Through testing and analyzing of more than 700 data points from over 100 samples containing calcium and other minerals, and vitamin K2 MK-7, Kappa Bioscience found low recovery of MK-7 in finished products and decreased stability over time. These results were irrespective of MK-7 origin or geographical location.
Trials conducted with the new product, K2VITAL Delta, both within Kappa Bioscience and selected customers, have proven K2VITAL Delta has a unique, stable recovery rate of MK-7 well above 95% in finished consumer products where calcium and other minerals are present.
“Our main objective is to make vitamin K2 available for all. To achieve this we have to provide the industry with an easy-to-use product which meets all quality standards set by our customers at an affordable price. With K2VITAL Delta, we have introduced a new standard for vitamin K2, and our customers are left with the security that this meets their requirement for a wide range of applications,” said Egil Greve, CEO Kappa Bioscience AS.
K2VITAL Delta creates a new ingredient standard for vitamin K2 MK-7 with a microencapsulation technology that protects the vitamin K2 molecule, enabling it to survive processing conditions and increase shelf life stability. For manufacturers of calcium and other mineral formulations, this offers numerous new benefits, such as greater stability resulting in longer shelf life, lower cost in use (due to lower overage), better blending characteristics and flow-ability, and confirmed presence of vitamin K2 in the finished product. K2VITAL Delta supports label claims made on finished products, while maintaining “free from” certification. For more information: www.k2vital.com.